Hemab Q2: $457.5M Cash, Sutacimig Phase 3 Greenlit, New HMB-003 Program Unveiled

summarizeSummary

Hemab Therapeutics reported Q2 2026 financial results with $457.5M in cash, received FDA endorsement to proceed to a Phase 3 trial for sutacimig in GT, and unveiled a new program, HMB-003, for heavy menstrual bleeding.

check_boxKey Events · Earnings and Guidance · COAG

• FDA Endorses Sutacimig Phase 3

  FDA endorsed the clinical data package as sufficient to proceed to a Phase 3 pivotal trial in Glanzmann thrombasthenia; initiation planned for 2H 2026.

• Strong Cash Position

  Cash, cash equivalents, and marketable securities totaled $457.5 million as of June 30, 2026, providing runway into 2029.

• HMB-002 Positive Phase 1/2 Data

  HMB-002 demonstrated ≥2.4-fold increase in VWF and FVIII, with 8 of 9 evaluable patients having zero treated bleeds in 28 days post-dosing.

• New Program HMB-003 Unveiled

  HMB-003, a novel peptide-based plasmin inhibitor, is being developed initially for heavy menstrual bleeding, with first-in-human studies planned for 2H 2026.

auto_awesomeAnalysis · COAG · Life Sciences

Hemab reported Q2 results with a strong cash position of $457.5 million, extending runway into 2029. The FDA endorsed the sutacimig data package for a Phase 3 pivotal trial in Glanzmann thrombasthenia, a major regulatory milestone. New clinical data for HMB-002 in Von Willebrand Disease showed robust proof of mechanism and encouraging early efficacy signals. The company also unveiled HMB-003, a novel antifibrinolytic for heavy menstrual bleeding, expanding its pipeline. These updates materially advance the investment thesis by de-risking the lead program and broadening the pipeline.